nodes	percent_of_prediction	percent_of_DWPC	metapath
Irinotecan—stomach cancer—esophageal cancer	0.175	0.372	CtDrD
Irinotecan—pancreatic cancer—esophageal cancer	0.163	0.347	CtDrD
Irinotecan—ABCC2—esophageal cancer	0.134	0.731	CbGaD
Irinotecan—lung cancer—esophageal cancer	0.132	0.28	CtDrD
Irinotecan—CES1—Capecitabine—esophageal cancer	0.09	0.4	CbGbCtD
Irinotecan—ABCB1—esophageal cancer	0.0492	0.269	CbGaD
Irinotecan—BCHE—Cisplatin—esophageal cancer	0.0176	0.0782	CbGbCtD
Irinotecan—ABCC2—Carboplatin—esophageal cancer	0.016	0.0713	CbGbCtD
Irinotecan—ABCG2—Carboplatin—esophageal cancer	0.0145	0.0644	CbGbCtD
Irinotecan—ABCC2—Cisplatin—esophageal cancer	0.0137	0.0609	CbGbCtD
Irinotecan—ABCG2—Cisplatin—esophageal cancer	0.0124	0.055	CbGbCtD
Irinotecan—ABCC1—Methotrexate—esophageal cancer	0.012	0.0534	CbGbCtD
Irinotecan—SLCO1B1—Methotrexate—esophageal cancer	0.0101	0.045	CbGbCtD
Irinotecan—ABCC2—Methotrexate—esophageal cancer	0.00889	0.0395	CbGbCtD
Irinotecan—CYP2B6—Cisplatin—esophageal cancer	0.00871	0.0387	CbGbCtD
Irinotecan—ABCG2—Methotrexate—esophageal cancer	0.00804	0.0357	CbGbCtD
Irinotecan—ALB—Methotrexate—esophageal cancer	0.00554	0.0246	CbGbCtD
Irinotecan—ABCB1—Cisplatin—esophageal cancer	0.00446	0.0198	CbGbCtD
Irinotecan—ABCB1—Methotrexate—esophageal cancer	0.0029	0.0129	CbGbCtD
Irinotecan—CES1—larynx—esophageal cancer	0.0027	0.137	CbGeAlD
Irinotecan—BCHE—diaphragm—esophageal cancer	0.00251	0.128	CbGeAlD
Irinotecan—TOP1MT—lung—esophageal cancer	0.000786	0.0399	CbGeAlD
Irinotecan—Topotecan—ABCB1—esophageal cancer	0.000784	1	CrCbGaD
Irinotecan—CES1—neck—esophageal cancer	0.000716	0.0364	CbGeAlD
Irinotecan—TOP1—bronchus—esophageal cancer	0.000643	0.0327	CbGeAlD
Irinotecan—TOP1—smooth muscle tissue—esophageal cancer	0.000629	0.0319	CbGeAlD
Irinotecan—CES2—bronchus—esophageal cancer	0.000583	0.0296	CbGeAlD
Irinotecan—TOP1—trachea—esophageal cancer	0.000577	0.0293	CbGeAlD
Irinotecan—CES2—smooth muscle tissue—esophageal cancer	0.00057	0.029	CbGeAlD
Irinotecan—UGT1A9—digestive system—esophageal cancer	0.000559	0.0284	CbGeAlD
Irinotecan—TOP1MT—lymph node—esophageal cancer	0.000538	0.0273	CbGeAlD
Irinotecan—CES2—trachea—esophageal cancer	0.000523	0.0266	CbGeAlD
Irinotecan—CES2—digestive system—esophageal cancer	0.00045	0.0229	CbGeAlD
Irinotecan—Serum creatinine increased—Cisplatin—esophageal cancer	0.000436	0.00901	CcSEcCtD
Irinotecan—TOP1—lung—esophageal cancer	0.000415	0.0211	CbGeAlD
Irinotecan—Rectal disorder—Capecitabine—esophageal cancer	0.000403	0.00833	CcSEcCtD
Irinotecan—Lymphopenia—Capecitabine—esophageal cancer	0.000386	0.00798	CcSEcCtD
Irinotecan—Sudden death—Capecitabine—esophageal cancer	0.000386	0.00798	CcSEcCtD
Irinotecan—UGT1A1—digestive system—esophageal cancer	0.000383	0.0195	CbGeAlD
Irinotecan—CES2—lung—esophageal cancer	0.000376	0.0191	CbGeAlD
Irinotecan—Anorectal disorder—Capecitabine—esophageal cancer	0.000376	0.00777	CcSEcCtD
Irinotecan—Intestinal perforation—Methotrexate—esophageal cancer	0.000372	0.00769	CcSEcCtD
Irinotecan—CES1—digestive system—esophageal cancer	0.000371	0.0188	CbGeAlD
Irinotecan—Mucosal inflammation—Capecitabine—esophageal cancer	0.000357	0.00738	CcSEcCtD
Irinotecan—Febrile neutropenia—Capecitabine—esophageal cancer	0.000328	0.00679	CcSEcCtD
Irinotecan—SLC22A3—smooth muscle tissue—esophageal cancer	0.000326	0.0166	CbGeAlD
Irinotecan—Infection—Carboplatin—esophageal cancer	0.000324	0.0067	CcSEcCtD
Irinotecan—Serum creatinine increased—Capecitabine—esophageal cancer	0.000321	0.00664	CcSEcCtD
Irinotecan—SLCO1B1—digestive system—esophageal cancer	0.000319	0.0162	CbGeAlD
Irinotecan—Lung infiltration—Methotrexate—esophageal cancer	0.000314	0.00648	CcSEcCtD
Irinotecan—Hypomagnesaemia—Capecitabine—esophageal cancer	0.000311	0.00643	CcSEcCtD
Irinotecan—CES1—lung—esophageal cancer	0.00031	0.0157	CbGeAlD
Irinotecan—Embolism—Capecitabine—esophageal cancer	0.000308	0.00636	CcSEcCtD
Irinotecan—Extravasation—Cisplatin—esophageal cancer	0.000307	0.00635	CcSEcCtD
Irinotecan—Intestinal obstruction—Capecitabine—esophageal cancer	0.00029	0.00599	CcSEcCtD
Irinotecan—Sudden death—Methotrexate—esophageal cancer	0.000287	0.00594	CcSEcCtD
Irinotecan—TOP1—lymph node—esophageal cancer	0.000284	0.0144	CbGeAlD
Irinotecan—Dysarthria—Cisplatin—esophageal cancer	0.000283	0.00586	CcSEcCtD
Irinotecan—Ulcer—Cisplatin—esophageal cancer	0.000283	0.00586	CcSEcCtD
Irinotecan—Thrombosis—Capecitabine—esophageal cancer	0.000279	0.00577	CcSEcCtD
Irinotecan—Hepatomegaly—Capecitabine—esophageal cancer	0.000279	0.00577	CcSEcCtD
Irinotecan—Ileus—Capecitabine—esophageal cancer	0.000279	0.00577	CcSEcCtD
Irinotecan—Pain—Carboplatin—esophageal cancer	0.000279	0.00576	CcSEcCtD
Irinotecan—ABCC1—bronchus—esophageal cancer	0.000275	0.014	CbGeAlD
Irinotecan—Hiccups—Cisplatin—esophageal cancer	0.000268	0.00554	CcSEcCtD
Irinotecan—Mucosal inflammation—Methotrexate—esophageal cancer	0.000266	0.00549	CcSEcCtD
Irinotecan—Body temperature increased—Carboplatin—esophageal cancer	0.000258	0.00533	CcSEcCtD
Irinotecan—CES2—lymph node—esophageal cancer	0.000257	0.0131	CbGeAlD
Irinotecan—ABCC1—trachea—esophageal cancer	0.000247	0.0126	CbGeAlD
Irinotecan—Myocardial ischaemia—Capecitabine—esophageal cancer	0.000246	0.00508	CcSEcCtD
Irinotecan—Febrile neutropenia—Methotrexate—esophageal cancer	0.000244	0.00505	CcSEcCtD
Irinotecan—ABCC2—digestive system—esophageal cancer	0.000242	0.0123	CbGeAlD
Irinotecan—BCHE—bronchus—esophageal cancer	0.000236	0.012	CbGeAlD
Irinotecan—BCHE—smooth muscle tissue—esophageal cancer	0.000231	0.0117	CbGeAlD
Irinotecan—Embolism—Methotrexate—esophageal cancer	0.000229	0.00474	CcSEcCtD
Irinotecan—Hyperbilirubinaemia—Capecitabine—esophageal cancer	0.000217	0.00449	CcSEcCtD
Irinotecan—SLC22A3—lung—esophageal cancer	0.000215	0.0109	CbGeAlD
Irinotecan—Lacrimation increased—Capecitabine—esophageal cancer	0.000214	0.00443	CcSEcCtD
Irinotecan—BCHE—trachea—esophageal cancer	0.000212	0.0108	CbGeAlD
Irinotecan—ACHE—lymph node—esophageal cancer	0.000212	0.0108	CbGeAlD
Irinotecan—CES1—lymph node—esophageal cancer	0.000212	0.0108	CbGeAlD
Irinotecan—Renal failure acute—Cisplatin—esophageal cancer	0.000211	0.00436	CcSEcCtD
Irinotecan—CYP2B6—bronchus—esophageal cancer	0.00021	0.0107	CbGeAlD
Irinotecan—Blood bilirubin increased—Capecitabine—esophageal cancer	0.000209	0.00432	CcSEcCtD
Irinotecan—Ulcer—Capecitabine—esophageal cancer	0.000209	0.00432	CcSEcCtD
Irinotecan—Dysarthria—Capecitabine—esophageal cancer	0.000209	0.00432	CcSEcCtD
Irinotecan—Lung disorder—Methotrexate—esophageal cancer	0.000208	0.0043	CcSEcCtD
Irinotecan—Gait disturbance—Capecitabine—esophageal cancer	0.000202	0.00419	CcSEcCtD
Irinotecan—Anaphylactoid reaction—Cisplatin—esophageal cancer	0.000201	0.00416	CcSEcCtD
Irinotecan—Cerebrovascular accident—Cisplatin—esophageal cancer	0.000198	0.0041	CcSEcCtD
Irinotecan—Phosphatase alkaline increased—Capecitabine—esophageal cancer	0.000198	0.00409	CcSEcCtD
Irinotecan—Hiccups—Capecitabine—esophageal cancer	0.000198	0.00409	CcSEcCtD
Irinotecan—Pulmonary embolism—Capecitabine—esophageal cancer	0.000198	0.00409	CcSEcCtD
Irinotecan—Hyponatraemia—Cisplatin—esophageal cancer	0.000195	0.00404	CcSEcCtD
Irinotecan—Gastrointestinal haemorrhage—Cisplatin—esophageal cancer	0.000194	0.00402	CcSEcCtD
Irinotecan—Colitis—Capecitabine—esophageal cancer	0.00019	0.00392	CcSEcCtD
Irinotecan—BCHE—digestive system—esophageal cancer	0.000182	0.00926	CbGeAlD
Irinotecan—Blood creatinine increased—Cisplatin—esophageal cancer	0.000182	0.00377	CcSEcCtD
Irinotecan—Dehydration—Cisplatin—esophageal cancer	0.000181	0.00374	CcSEcCtD
Irinotecan—Neoplasm—Capecitabine—esophageal cancer	0.000179	0.00369	CcSEcCtD
Irinotecan—ABCC1—lung—esophageal cancer	0.000178	0.00903	CbGeAlD
Irinotecan—Orthostatic hypotension—Cisplatin—esophageal cancer	0.000178	0.00367	CcSEcCtD
Irinotecan—Hypokalaemia—Cisplatin—esophageal cancer	0.000177	0.00366	CcSEcCtD
Irinotecan—Cramp muscle—Cisplatin—esophageal cancer	0.000175	0.00362	CcSEcCtD
Irinotecan—Aspartate aminotransferase increased—Cisplatin—esophageal cancer	0.000175	0.00362	CcSEcCtD
Irinotecan—Sepsis—Capecitabine—esophageal cancer	0.000171	0.00354	CcSEcCtD
Irinotecan—Speech disorder—Methotrexate—esophageal cancer	0.000171	0.00354	CcSEcCtD
Irinotecan—Extravasation—Methotrexate—esophageal cancer	0.000169	0.00349	CcSEcCtD
Irinotecan—Thrombophlebitis—Capecitabine—esophageal cancer	0.000166	0.00343	CcSEcCtD
Irinotecan—Blood alkaline phosphatase increased—Capecitabine—esophageal cancer	0.000165	0.00341	CcSEcCtD
Irinotecan—Pancreatitis—Cisplatin—esophageal cancer	0.000165	0.00341	CcSEcCtD
Irinotecan—Sweating increased—Cisplatin—esophageal cancer	0.000164	0.00339	CcSEcCtD
Irinotecan—CYP3A5—digestive system—esophageal cancer	0.000163	0.00831	CbGeAlD
Irinotecan—CYP2B6—digestive system—esophageal cancer	0.000162	0.00826	CbGeAlD
Irinotecan—Hyperbilirubinaemia—Methotrexate—esophageal cancer	0.000162	0.00334	CcSEcCtD
Irinotecan—Ulcer—Methotrexate—esophageal cancer	0.000155	0.00321	CcSEcCtD
Irinotecan—Dysarthria—Methotrexate—esophageal cancer	0.000155	0.00321	CcSEcCtD
Irinotecan—Renal failure acute—Capecitabine—esophageal cancer	0.000155	0.00321	CcSEcCtD
Irinotecan—BCHE—lung—esophageal cancer	0.000152	0.00773	CbGeAlD
Irinotecan—Dermatitis exfoliative—Capecitabine—esophageal cancer	0.000152	0.00314	CcSEcCtD
Irinotecan—Renal impairment—Capecitabine—esophageal cancer	0.000151	0.00312	CcSEcCtD
Irinotecan—Acute coronary syndrome—Cisplatin—esophageal cancer	0.000148	0.00306	CcSEcCtD
Irinotecan—Renal failure—Cisplatin—esophageal cancer	0.000147	0.00305	CcSEcCtD
Irinotecan—ALB—lymph node—esophageal cancer	0.000147	0.00748	CbGeAlD
Irinotecan—ABCG2—lung—esophageal cancer	0.000147	0.00747	CbGeAlD
Irinotecan—Pulmonary embolism—Methotrexate—esophageal cancer	0.000147	0.00304	CcSEcCtD
Irinotecan—SLC22A3—lymph node—esophageal cancer	0.000147	0.00747	CbGeAlD
Irinotecan—Myocardial infarction—Cisplatin—esophageal cancer	0.000147	0.00304	CcSEcCtD
Irinotecan—Cerebrovascular accident—Capecitabine—esophageal cancer	0.000146	0.00303	CcSEcCtD
Irinotecan—Stomatitis—Cisplatin—esophageal cancer	0.000146	0.00302	CcSEcCtD
Irinotecan—Hyponatraemia—Capecitabine—esophageal cancer	0.000144	0.00298	CcSEcCtD
Irinotecan—Gastrointestinal haemorrhage—Capecitabine—esophageal cancer	0.000143	0.00297	CcSEcCtD
Irinotecan—Osteoarthritis—Capecitabine—esophageal cancer	0.000143	0.00297	CcSEcCtD
Irinotecan—ABCC2—lymph node—esophageal cancer	0.000138	0.00701	CbGeAlD
Irinotecan—Bradycardia—Cisplatin—esophageal cancer	0.000137	0.00283	CcSEcCtD
Irinotecan—CYP3A5—lung—esophageal cancer	0.000137	0.00694	CbGeAlD
Irinotecan—Cardiac arrest—Capecitabine—esophageal cancer	0.000136	0.00282	CcSEcCtD
Irinotecan—CYP2B6—lung—esophageal cancer	0.000136	0.00689	CbGeAlD
Irinotecan—Blood creatinine increased—Capecitabine—esophageal cancer	0.000134	0.00278	CcSEcCtD
Irinotecan—Dehydration—Capecitabine—esophageal cancer	0.000133	0.00276	CcSEcCtD
Irinotecan—Neoplasm—Methotrexate—esophageal cancer	0.000133	0.00275	CcSEcCtD
Irinotecan—Connective tissue disorder—Cisplatin—esophageal cancer	0.000132	0.00273	CcSEcCtD
Irinotecan—Orthostatic hypotension—Capecitabine—esophageal cancer	0.000131	0.00271	CcSEcCtD
Irinotecan—Hypokalaemia—Capecitabine—esophageal cancer	0.00013	0.0027	CcSEcCtD
Irinotecan—Visual impairment—Cisplatin—esophageal cancer	0.00013	0.00268	CcSEcCtD
Irinotecan—Aspartate aminotransferase increased—Capecitabine—esophageal cancer	0.000129	0.00267	CcSEcCtD
Irinotecan—Sepsis—Methotrexate—esophageal cancer	0.000128	0.00264	CcSEcCtD
Irinotecan—Flushing—Cisplatin—esophageal cancer	0.000125	0.00258	CcSEcCtD
Irinotecan—Cardiac disorder—Cisplatin—esophageal cancer	0.000125	0.00258	CcSEcCtD
Irinotecan—Abdominal distension—Capecitabine—esophageal cancer	0.000125	0.00258	CcSEcCtD
Irinotecan—Thrombophlebitis—Methotrexate—esophageal cancer	0.000123	0.00255	CcSEcCtD
Irinotecan—CYP3A4—digestive system—esophageal cancer	0.000123	0.00623	CbGeAlD
Irinotecan—Immune system disorder—Cisplatin—esophageal cancer	0.000122	0.00251	CcSEcCtD
Irinotecan—ABCC1—lymph node—esophageal cancer	0.000122	0.00617	CbGeAlD
Irinotecan—Mediastinal disorder—Cisplatin—esophageal cancer	0.000121	0.00251	CcSEcCtD
Irinotecan—Sweating increased—Capecitabine—esophageal cancer	0.000121	0.0025	CcSEcCtD
Irinotecan—Angina pectoris—Capecitabine—esophageal cancer	0.000121	0.0025	CcSEcCtD
Irinotecan—Arrhythmia—Cisplatin—esophageal cancer	0.00012	0.00249	CcSEcCtD
Irinotecan—Alopecia—Cisplatin—esophageal cancer	0.000119	0.00246	CcSEcCtD
Irinotecan—Neutropenia—Capecitabine—esophageal cancer	0.000116	0.0024	CcSEcCtD
Irinotecan—Renal failure acute—Methotrexate—esophageal cancer	0.000116	0.00239	CcSEcCtD
Irinotecan—Flatulence—Cisplatin—esophageal cancer	0.000115	0.00239	CcSEcCtD
Irinotecan—Upper respiratory tract infection—Capecitabine—esophageal cancer	0.000115	0.00238	CcSEcCtD
Irinotecan—ABCB1—epithelium—esophageal cancer	0.000114	0.0058	CbGeAlD
Irinotecan—Dermatitis exfoliative—Methotrexate—esophageal cancer	0.000113	0.00234	CcSEcCtD
Irinotecan—Visual disturbance—Methotrexate—esophageal cancer	0.000113	0.00233	CcSEcCtD
Irinotecan—Muscle spasms—Cisplatin—esophageal cancer	0.000113	0.00233	CcSEcCtD
Irinotecan—Weight decreased—Capecitabine—esophageal cancer	0.000112	0.00232	CcSEcCtD
Irinotecan—Pneumonia—Capecitabine—esophageal cancer	0.000111	0.0023	CcSEcCtD
Irinotecan—Anaphylactoid reaction—Methotrexate—esophageal cancer	0.00011	0.00228	CcSEcCtD
Irinotecan—Acute coronary syndrome—Capecitabine—esophageal cancer	0.000109	0.00225	CcSEcCtD
Irinotecan—Cerebrovascular accident—Methotrexate—esophageal cancer	0.000109	0.00225	CcSEcCtD
Irinotecan—Ill-defined disorder—Cisplatin—esophageal cancer	0.000109	0.00225	CcSEcCtD
Irinotecan—Renal failure—Capecitabine—esophageal cancer	0.000109	0.00225	CcSEcCtD
Irinotecan—Myocardial infarction—Capecitabine—esophageal cancer	0.000108	0.00224	CcSEcCtD
Irinotecan—Anaemia—Cisplatin—esophageal cancer	0.000108	0.00224	CcSEcCtD
Irinotecan—Stomatitis—Capecitabine—esophageal cancer	0.000108	0.00223	CcSEcCtD
Irinotecan—Jaundice—Capecitabine—esophageal cancer	0.000108	0.00223	CcSEcCtD
Irinotecan—Osteoarthritis—Methotrexate—esophageal cancer	0.000107	0.00221	CcSEcCtD
Irinotecan—Malaise—Cisplatin—esophageal cancer	0.000106	0.00218	CcSEcCtD
Irinotecan—Leukopenia—Cisplatin—esophageal cancer	0.000105	0.00217	CcSEcCtD
Irinotecan—BCHE—lymph node—esophageal cancer	0.000104	0.00529	CbGeAlD
Irinotecan—Bradycardia—Capecitabine—esophageal cancer	0.000101	0.00209	CcSEcCtD
Irinotecan—ABCB1—trachea—esophageal cancer	0.000101	0.00513	CbGeAlD
Irinotecan—ABCG2—lymph node—esophageal cancer	0.000101	0.00511	CbGeAlD
Irinotecan—Haemoglobin—Capecitabine—esophageal cancer	9.97e-05	0.00206	CcSEcCtD
Irinotecan—Rhinitis—Capecitabine—esophageal cancer	9.94e-05	0.00206	CcSEcCtD
Irinotecan—Haemorrhage—Capecitabine—esophageal cancer	9.92e-05	0.00205	CcSEcCtD
Irinotecan—Discomfort—Cisplatin—esophageal cancer	9.85e-05	0.00204	CcSEcCtD
Irinotecan—Connective tissue disorder—Capecitabine—esophageal cancer	9.75e-05	0.00202	CcSEcCtD
Irinotecan—Oedema—Cisplatin—esophageal cancer	9.56e-05	0.00198	CcSEcCtD
Irinotecan—Anaphylactic shock—Cisplatin—esophageal cancer	9.56e-05	0.00198	CcSEcCtD
Irinotecan—Visual impairment—Capecitabine—esophageal cancer	9.56e-05	0.00198	CcSEcCtD
Irinotecan—Infection—Cisplatin—esophageal cancer	9.5e-05	0.00196	CcSEcCtD
Irinotecan—Nervous system disorder—Cisplatin—esophageal cancer	9.37e-05	0.00194	CcSEcCtD
Irinotecan—Thrombocytopenia—Cisplatin—esophageal cancer	9.36e-05	0.00194	CcSEcCtD
Irinotecan—Hyperhidrosis—Cisplatin—esophageal cancer	9.24e-05	0.00191	CcSEcCtD
Irinotecan—Cardiac disorder—Capecitabine—esophageal cancer	9.2e-05	0.0019	CcSEcCtD
Irinotecan—Flushing—Capecitabine—esophageal cancer	9.2e-05	0.0019	CcSEcCtD
Irinotecan—Anorexia—Cisplatin—esophageal cancer	9.11e-05	0.00188	CcSEcCtD
Irinotecan—Pancreatitis—Methotrexate—esophageal cancer	9.04e-05	0.00187	CcSEcCtD
Irinotecan—Angiopathy—Capecitabine—esophageal cancer	9e-05	0.00186	CcSEcCtD
Irinotecan—Immune system disorder—Capecitabine—esophageal cancer	8.96e-05	0.00185	CcSEcCtD
Irinotecan—Mediastinal disorder—Capecitabine—esophageal cancer	8.94e-05	0.00185	CcSEcCtD
Irinotecan—Hypotension—Cisplatin—esophageal cancer	8.93e-05	0.00185	CcSEcCtD
Irinotecan—Chills—Capecitabine—esophageal cancer	8.9e-05	0.00184	CcSEcCtD
Irinotecan—Arrhythmia—Capecitabine—esophageal cancer	8.86e-05	0.00183	CcSEcCtD
Irinotecan—Alopecia—Capecitabine—esophageal cancer	8.76e-05	0.00181	CcSEcCtD
Irinotecan—ABCB1—digestive system—esophageal cancer	8.68e-05	0.00441	CbGeAlD
Irinotecan—Neutropenia—Methotrexate—esophageal cancer	8.63e-05	0.00178	CcSEcCtD
Irinotecan—Paraesthesia—Cisplatin—esophageal cancer	8.58e-05	0.00178	CcSEcCtD
Irinotecan—Upper respiratory tract infection—Methotrexate—esophageal cancer	8.57e-05	0.00177	CcSEcCtD
Irinotecan—Dyspnoea—Cisplatin—esophageal cancer	8.52e-05	0.00176	CcSEcCtD
Irinotecan—Flatulence—Capecitabine—esophageal cancer	8.51e-05	0.00176	CcSEcCtD
Irinotecan—Back pain—Capecitabine—esophageal cancer	8.35e-05	0.00173	CcSEcCtD
Irinotecan—Decreased appetite—Cisplatin—esophageal cancer	8.31e-05	0.00172	CcSEcCtD
Irinotecan—Muscle spasms—Capecitabine—esophageal cancer	8.3e-05	0.00172	CcSEcCtD
Irinotecan—Pneumonia—Methotrexate—esophageal cancer	8.27e-05	0.00171	CcSEcCtD
Irinotecan—Gastrointestinal disorder—Cisplatin—esophageal cancer	8.25e-05	0.00171	CcSEcCtD
Irinotecan—Pain—Cisplatin—esophageal cancer	8.17e-05	0.00169	CcSEcCtD
Irinotecan—Renal failure—Methotrexate—esophageal cancer	8.08e-05	0.00167	CcSEcCtD
Irinotecan—Stomatitis—Methotrexate—esophageal cancer	8.02e-05	0.00166	CcSEcCtD
Irinotecan—Ill-defined disorder—Capecitabine—esophageal cancer	8.01e-05	0.00166	CcSEcCtD
Irinotecan—Anaemia—Capecitabine—esophageal cancer	7.98e-05	0.00165	CcSEcCtD
Irinotecan—Sweating—Methotrexate—esophageal cancer	7.88e-05	0.00163	CcSEcCtD
Irinotecan—Feeling abnormal—Cisplatin—esophageal cancer	7.88e-05	0.00163	CcSEcCtD
Irinotecan—Malaise—Capecitabine—esophageal cancer	7.79e-05	0.00161	CcSEcCtD
Irinotecan—Vertigo—Capecitabine—esophageal cancer	7.76e-05	0.0016	CcSEcCtD
Irinotecan—Syncope—Capecitabine—esophageal cancer	7.74e-05	0.0016	CcSEcCtD
Irinotecan—Leukopenia—Capecitabine—esophageal cancer	7.73e-05	0.0016	CcSEcCtD
Irinotecan—Loss of consciousness—Capecitabine—esophageal cancer	7.59e-05	0.00157	CcSEcCtD
Irinotecan—Body temperature increased—Cisplatin—esophageal cancer	7.56e-05	0.00156	CcSEcCtD
Irinotecan—Cough—Capecitabine—esophageal cancer	7.53e-05	0.00156	CcSEcCtD
Irinotecan—Hypertension—Capecitabine—esophageal cancer	7.45e-05	0.00154	CcSEcCtD
Irinotecan—Haemoglobin—Methotrexate—esophageal cancer	7.42e-05	0.00153	CcSEcCtD
Irinotecan—Haemorrhage—Methotrexate—esophageal cancer	7.38e-05	0.00153	CcSEcCtD
Irinotecan—Discomfort—Capecitabine—esophageal cancer	7.26e-05	0.0015	CcSEcCtD
Irinotecan—ABCB1—lung—esophageal cancer	7.25e-05	0.00369	CbGeAlD
Irinotecan—Visual impairment—Methotrexate—esophageal cancer	7.12e-05	0.00147	CcSEcCtD
Irinotecan—Confusional state—Capecitabine—esophageal cancer	7.1e-05	0.00147	CcSEcCtD
Irinotecan—Oedema—Capecitabine—esophageal cancer	7.05e-05	0.00146	CcSEcCtD
Irinotecan—Hypersensitivity—Cisplatin—esophageal cancer	7.04e-05	0.00146	CcSEcCtD
Irinotecan—Infection—Capecitabine—esophageal cancer	7e-05	0.00145	CcSEcCtD
Irinotecan—Shock—Capecitabine—esophageal cancer	6.93e-05	0.00143	CcSEcCtD
Irinotecan—Nervous system disorder—Capecitabine—esophageal cancer	6.91e-05	0.00143	CcSEcCtD
Irinotecan—Thrombocytopenia—Capecitabine—esophageal cancer	6.9e-05	0.00143	CcSEcCtD
Irinotecan—Asthenia—Cisplatin—esophageal cancer	6.86e-05	0.00142	CcSEcCtD
Irinotecan—Cardiac disorder—Methotrexate—esophageal cancer	6.85e-05	0.00142	CcSEcCtD
Irinotecan—Hyperhidrosis—Capecitabine—esophageal cancer	6.81e-05	0.00141	CcSEcCtD
Irinotecan—Anorexia—Capecitabine—esophageal cancer	6.72e-05	0.00139	CcSEcCtD
Irinotecan—Angiopathy—Methotrexate—esophageal cancer	6.7e-05	0.00139	CcSEcCtD
Irinotecan—Immune system disorder—Methotrexate—esophageal cancer	6.67e-05	0.00138	CcSEcCtD
Irinotecan—Mediastinal disorder—Methotrexate—esophageal cancer	6.65e-05	0.00138	CcSEcCtD
Irinotecan—Chills—Methotrexate—esophageal cancer	6.62e-05	0.00137	CcSEcCtD
Irinotecan—Hypotension—Capecitabine—esophageal cancer	6.58e-05	0.00136	CcSEcCtD
Irinotecan—Diarrhoea—Cisplatin—esophageal cancer	6.54e-05	0.00135	CcSEcCtD
Irinotecan—Alopecia—Methotrexate—esophageal cancer	6.52e-05	0.00135	CcSEcCtD
Irinotecan—Insomnia—Capecitabine—esophageal cancer	6.37e-05	0.00132	CcSEcCtD
Irinotecan—Paraesthesia—Capecitabine—esophageal cancer	6.33e-05	0.00131	CcSEcCtD
Irinotecan—Dyspnoea—Capecitabine—esophageal cancer	6.28e-05	0.0013	CcSEcCtD
Irinotecan—Back pain—Methotrexate—esophageal cancer	6.22e-05	0.00129	CcSEcCtD
Irinotecan—Dyspepsia—Capecitabine—esophageal cancer	6.2e-05	0.00128	CcSEcCtD
Irinotecan—Decreased appetite—Capecitabine—esophageal cancer	6.13e-05	0.00127	CcSEcCtD
Irinotecan—Gastrointestinal disorder—Capecitabine—esophageal cancer	6.08e-05	0.00126	CcSEcCtD
Irinotecan—Vomiting—Cisplatin—esophageal cancer	6.08e-05	0.00126	CcSEcCtD
Irinotecan—Fatigue—Capecitabine—esophageal cancer	6.08e-05	0.00126	CcSEcCtD
Irinotecan—Rash—Cisplatin—esophageal cancer	6.03e-05	0.00125	CcSEcCtD
Irinotecan—Pain—Capecitabine—esophageal cancer	6.03e-05	0.00125	CcSEcCtD
Irinotecan—Constipation—Capecitabine—esophageal cancer	6.03e-05	0.00125	CcSEcCtD
Irinotecan—Dermatitis—Cisplatin—esophageal cancer	6.02e-05	0.00125	CcSEcCtD
Irinotecan—Ill-defined disorder—Methotrexate—esophageal cancer	5.96e-05	0.00123	CcSEcCtD
Irinotecan—Anaemia—Methotrexate—esophageal cancer	5.94e-05	0.00123	CcSEcCtD
Irinotecan—Feeling abnormal—Capecitabine—esophageal cancer	5.81e-05	0.0012	CcSEcCtD
Irinotecan—Malaise—Methotrexate—esophageal cancer	5.8e-05	0.0012	CcSEcCtD
Irinotecan—Vertigo—Methotrexate—esophageal cancer	5.77e-05	0.00119	CcSEcCtD
Irinotecan—Gastrointestinal pain—Capecitabine—esophageal cancer	5.76e-05	0.00119	CcSEcCtD
Irinotecan—Leukopenia—Methotrexate—esophageal cancer	5.75e-05	0.00119	CcSEcCtD
Irinotecan—Nausea—Cisplatin—esophageal cancer	5.68e-05	0.00117	CcSEcCtD
Irinotecan—Cough—Methotrexate—esophageal cancer	5.61e-05	0.00116	CcSEcCtD
Irinotecan—Abdominal pain—Capecitabine—esophageal cancer	5.57e-05	0.00115	CcSEcCtD
Irinotecan—Body temperature increased—Capecitabine—esophageal cancer	5.57e-05	0.00115	CcSEcCtD
Irinotecan—Discomfort—Methotrexate—esophageal cancer	5.41e-05	0.00112	CcSEcCtD
Irinotecan—Confusional state—Methotrexate—esophageal cancer	5.29e-05	0.00109	CcSEcCtD
Irinotecan—Anaphylactic shock—Methotrexate—esophageal cancer	5.25e-05	0.00108	CcSEcCtD
Irinotecan—Infection—Methotrexate—esophageal cancer	5.21e-05	0.00108	CcSEcCtD
Irinotecan—Hypersensitivity—Capecitabine—esophageal cancer	5.19e-05	0.00107	CcSEcCtD
Irinotecan—Nervous system disorder—Methotrexate—esophageal cancer	5.14e-05	0.00106	CcSEcCtD
Irinotecan—Thrombocytopenia—Methotrexate—esophageal cancer	5.14e-05	0.00106	CcSEcCtD
Irinotecan—Hyperhidrosis—Methotrexate—esophageal cancer	5.07e-05	0.00105	CcSEcCtD
Irinotecan—Asthenia—Capecitabine—esophageal cancer	5.06e-05	0.00105	CcSEcCtD
Irinotecan—Anorexia—Methotrexate—esophageal cancer	5e-05	0.00103	CcSEcCtD
Irinotecan—ABCB1—lymph node—esophageal cancer	4.96e-05	0.00252	CbGeAlD
Irinotecan—Hypotension—Methotrexate—esophageal cancer	4.9e-05	0.00101	CcSEcCtD
Irinotecan—Diarrhoea—Capecitabine—esophageal cancer	4.82e-05	0.000997	CcSEcCtD
Irinotecan—Insomnia—Methotrexate—esophageal cancer	4.74e-05	0.000981	CcSEcCtD
Irinotecan—Paraesthesia—Methotrexate—esophageal cancer	4.71e-05	0.000974	CcSEcCtD
Irinotecan—Dyspnoea—Methotrexate—esophageal cancer	4.68e-05	0.000967	CcSEcCtD
Irinotecan—Somnolence—Methotrexate—esophageal cancer	4.66e-05	0.000964	CcSEcCtD
Irinotecan—Dizziness—Capecitabine—esophageal cancer	4.66e-05	0.000964	CcSEcCtD
Irinotecan—Dyspepsia—Methotrexate—esophageal cancer	4.62e-05	0.000955	CcSEcCtD
Irinotecan—Decreased appetite—Methotrexate—esophageal cancer	4.56e-05	0.000943	CcSEcCtD
Irinotecan—Gastrointestinal disorder—Methotrexate—esophageal cancer	4.53e-05	0.000937	CcSEcCtD
Irinotecan—Fatigue—Methotrexate—esophageal cancer	4.52e-05	0.000935	CcSEcCtD
Irinotecan—Pain—Methotrexate—esophageal cancer	4.49e-05	0.000928	CcSEcCtD
Irinotecan—Vomiting—Capecitabine—esophageal cancer	4.48e-05	0.000927	CcSEcCtD
Irinotecan—Rash—Capecitabine—esophageal cancer	4.44e-05	0.000919	CcSEcCtD
Irinotecan—Dermatitis—Capecitabine—esophageal cancer	4.44e-05	0.000918	CcSEcCtD
Irinotecan—Headache—Capecitabine—esophageal cancer	4.41e-05	0.000913	CcSEcCtD
Irinotecan—Feeling abnormal—Methotrexate—esophageal cancer	4.32e-05	0.000894	CcSEcCtD
Irinotecan—Gastrointestinal pain—Methotrexate—esophageal cancer	4.29e-05	0.000887	CcSEcCtD
Irinotecan—Nausea—Capecitabine—esophageal cancer	4.19e-05	0.000866	CcSEcCtD
Irinotecan—Abdominal pain—Methotrexate—esophageal cancer	4.15e-05	0.000858	CcSEcCtD
Irinotecan—Body temperature increased—Methotrexate—esophageal cancer	4.15e-05	0.000858	CcSEcCtD
Irinotecan—Hypersensitivity—Methotrexate—esophageal cancer	3.86e-05	0.000799	CcSEcCtD
Irinotecan—Asthenia—Methotrexate—esophageal cancer	3.76e-05	0.000778	CcSEcCtD
Irinotecan—Diarrhoea—Methotrexate—esophageal cancer	3.59e-05	0.000742	CcSEcCtD
Irinotecan—Dizziness—Methotrexate—esophageal cancer	3.47e-05	0.000717	CcSEcCtD
Irinotecan—Vomiting—Methotrexate—esophageal cancer	3.34e-05	0.00069	CcSEcCtD
Irinotecan—Rash—Methotrexate—esophageal cancer	3.31e-05	0.000684	CcSEcCtD
Irinotecan—Dermatitis—Methotrexate—esophageal cancer	3.3e-05	0.000683	CcSEcCtD
Irinotecan—Headache—Methotrexate—esophageal cancer	3.29e-05	0.00068	CcSEcCtD
Irinotecan—Nausea—Methotrexate—esophageal cancer	3.12e-05	0.000644	CcSEcCtD
Irinotecan—ABCG2—Metabolism—PSME2—esophageal cancer	4.86e-06	9.22e-05	CbGpPWpGaD
Irinotecan—ALB—Metabolism—ADH1B—esophageal cancer	4.85e-06	9.2e-05	CbGpPWpGaD
Irinotecan—ABCB1—Metabolism—PLCE1—esophageal cancer	4.84e-06	9.19e-05	CbGpPWpGaD
Irinotecan—ABCB1—Metabolism—ADH7—esophageal cancer	4.84e-06	9.19e-05	CbGpPWpGaD
Irinotecan—ABCC1—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	4.82e-06	9.15e-05	CbGpPWpGaD
Irinotecan—CYP3A7—Metabolism—PSME2—esophageal cancer	4.82e-06	9.14e-05	CbGpPWpGaD
Irinotecan—CYP3A7—Metabolism—PSME1—esophageal cancer	4.82e-06	9.14e-05	CbGpPWpGaD
Irinotecan—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—esophageal cancer	4.8e-06	9.12e-05	CbGpPWpGaD
Irinotecan—CYP2B6—Metabolism—ALDOB—esophageal cancer	4.77e-06	9.05e-05	CbGpPWpGaD
Irinotecan—ABCC1—Metabolism—CYP1B1—esophageal cancer	4.77e-06	9.04e-05	CbGpPWpGaD
Irinotecan—ALB—Transmembrane transport of small molecules—HMOX1—esophageal cancer	4.74e-06	9e-05	CbGpPWpGaD
Irinotecan—BCHE—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	4.7e-06	8.93e-05	CbGpPWpGaD
Irinotecan—ABCC1—Disease—SMAD4—esophageal cancer	4.69e-06	8.89e-05	CbGpPWpGaD
Irinotecan—CYP3A5—Metabolism—ALDOB—esophageal cancer	4.66e-06	8.85e-05	CbGpPWpGaD
Irinotecan—UGT1A1—Metabolism—CYP19A1—esophageal cancer	4.65e-06	8.82e-05	CbGpPWpGaD
Irinotecan—BCHE—Metabolism—CYP1B1—esophageal cancer	4.65e-06	8.82e-05	CbGpPWpGaD
Irinotecan—UGT1A9—Metabolism—CYP19A1—esophageal cancer	4.65e-06	8.82e-05	CbGpPWpGaD
Irinotecan—ALB—Metabolism—TYMP—esophageal cancer	4.63e-06	8.79e-05	CbGpPWpGaD
Irinotecan—CYP2B6—Metabolism—GAPDH—esophageal cancer	4.59e-06	8.72e-05	CbGpPWpGaD
Irinotecan—SLCO1B1—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	4.58e-06	8.7e-05	CbGpPWpGaD
Irinotecan—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—esophageal cancer	4.57e-06	8.67e-05	CbGpPWpGaD
Irinotecan—CYP2B6—Metabolism—CRABP1—esophageal cancer	4.55e-06	8.64e-05	CbGpPWpGaD
Irinotecan—ALB—Transmembrane transport of small molecules—ABCB1—esophageal cancer	4.55e-06	8.63e-05	CbGpPWpGaD
Irinotecan—SLCO1B1—Metabolism—CYP1B1—esophageal cancer	4.53e-06	8.6e-05	CbGpPWpGaD
Irinotecan—ALB—Metabolism—CYP26A1—esophageal cancer	4.51e-06	8.55e-05	CbGpPWpGaD
Irinotecan—CYP3A5—Metabolism—GAPDH—esophageal cancer	4.49e-06	8.52e-05	CbGpPWpGaD
Irinotecan—ABCC1—Metabolism—CYP19A1—esophageal cancer	4.48e-06	8.5e-05	CbGpPWpGaD
Irinotecan—ACHE—Metabolism—HMOX1—esophageal cancer	4.47e-06	8.48e-05	CbGpPWpGaD
Irinotecan—CYP3A5—Metabolism—CRABP1—esophageal cancer	4.45e-06	8.44e-05	CbGpPWpGaD
Irinotecan—ALB—Metabolism—ALOX15—esophageal cancer	4.39e-06	8.33e-05	CbGpPWpGaD
Irinotecan—ACHE—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	4.39e-06	8.32e-05	CbGpPWpGaD
Irinotecan—BCHE—Metabolism—CYP19A1—esophageal cancer	4.37e-06	8.29e-05	CbGpPWpGaD
Irinotecan—CYP2B6—Metabolism—GNG7—esophageal cancer	4.33e-06	8.22e-05	CbGpPWpGaD
Irinotecan—ACHE—Metabolism—ABCB1—esophageal cancer	4.29e-06	8.14e-05	CbGpPWpGaD
Irinotecan—SLCO1B1—Metabolism—CYP19A1—esophageal cancer	4.26e-06	8.08e-05	CbGpPWpGaD
Irinotecan—ABCB1—Metabolism—ADH1B—esophageal cancer	4.25e-06	8.06e-05	CbGpPWpGaD
Irinotecan—UGT1A1—Metabolism—HMOX1—esophageal cancer	4.24e-06	8.05e-05	CbGpPWpGaD
Irinotecan—UGT1A9—Metabolism—HMOX1—esophageal cancer	4.24e-06	8.05e-05	CbGpPWpGaD
Irinotecan—CYP3A5—Metabolism—GNG7—esophageal cancer	4.23e-06	8.03e-05	CbGpPWpGaD
Irinotecan—ABCG2—Metabolism—CYP1B1—esophageal cancer	4.19e-06	7.96e-05	CbGpPWpGaD
Irinotecan—ALB—Metabolism—GSTO1—esophageal cancer	4.19e-06	7.95e-05	CbGpPWpGaD
Irinotecan—ALB—Metabolism—TPI1—esophageal cancer	4.19e-06	7.95e-05	CbGpPWpGaD
Irinotecan—UGT1A9—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	4.16e-06	7.9e-05	CbGpPWpGaD
Irinotecan—CYP3A7—Metabolism—CYP1B1—esophageal cancer	4.16e-06	7.89e-05	CbGpPWpGaD
Irinotecan—ABCB1—Transmembrane transport of small molecules—HMOX1—esophageal cancer	4.15e-06	7.88e-05	CbGpPWpGaD
Irinotecan—CYP3A4—Metabolism—SLC52A3—esophageal cancer	4.13e-06	7.83e-05	CbGpPWpGaD
Irinotecan—CYP3A4—Metabolism—BLVRB—esophageal cancer	4.13e-06	7.83e-05	CbGpPWpGaD
Irinotecan—ABCC1—Metabolism—HMOX1—esophageal cancer	4.09e-06	7.76e-05	CbGpPWpGaD
Irinotecan—UGT1A1—Metabolism—ABCB1—esophageal cancer	4.07e-06	7.72e-05	CbGpPWpGaD
Irinotecan—UGT1A9—Metabolism—ABCB1—esophageal cancer	4.07e-06	7.72e-05	CbGpPWpGaD
Irinotecan—ABCB1—Metabolism—TYMP—esophageal cancer	4.06e-06	7.7e-05	CbGpPWpGaD
Irinotecan—CYP2B6—Metabolism—ALDH2—esophageal cancer	4.06e-06	7.7e-05	CbGpPWpGaD
Irinotecan—ALB—Metabolism—ALDOB—esophageal cancer	4.02e-06	7.62e-05	CbGpPWpGaD
Irinotecan—ABCC1—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	4.01e-06	7.61e-05	CbGpPWpGaD
Irinotecan—BCHE—Metabolism—HMOX1—esophageal cancer	3.99e-06	7.57e-05	CbGpPWpGaD
Irinotecan—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—esophageal cancer	3.98e-06	7.56e-05	CbGpPWpGaD
Irinotecan—CYP3A5—Metabolism—ALDH2—esophageal cancer	3.97e-06	7.52e-05	CbGpPWpGaD
Irinotecan—ABCB1—Metabolism—CYP26A1—esophageal cancer	3.95e-06	7.49e-05	CbGpPWpGaD
Irinotecan—ABCG2—Metabolism—CYP19A1—esophageal cancer	3.94e-06	7.48e-05	CbGpPWpGaD
Irinotecan—ABCC1—Metabolism—ABCB1—esophageal cancer	3.93e-06	7.45e-05	CbGpPWpGaD
Irinotecan—ALB—Hemostasis—NOS2—esophageal cancer	3.91e-06	7.42e-05	CbGpPWpGaD
Irinotecan—BCHE—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	3.91e-06	7.42e-05	CbGpPWpGaD
Irinotecan—CYP3A7—Metabolism—CYP19A1—esophageal cancer	3.91e-06	7.42e-05	CbGpPWpGaD
Irinotecan—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—esophageal cancer	3.9e-06	7.39e-05	CbGpPWpGaD
Irinotecan—SLCO1B1—Metabolism—HMOX1—esophageal cancer	3.89e-06	7.37e-05	CbGpPWpGaD
Irinotecan—ALB—Metabolism—GAPDH—esophageal cancer	3.87e-06	7.34e-05	CbGpPWpGaD
Irinotecan—CYP2B6—Metabolism—GSTT1—esophageal cancer	3.86e-06	7.32e-05	CbGpPWpGaD
Irinotecan—ABCB1—Metabolism—ALOX15—esophageal cancer	3.85e-06	7.3e-05	CbGpPWpGaD
Irinotecan—ABCC1—Disease—HIF1A—esophageal cancer	3.84e-06	7.28e-05	CbGpPWpGaD
Irinotecan—ALB—Metabolism—CRABP1—esophageal cancer	3.83e-06	7.27e-05	CbGpPWpGaD
Irinotecan—BCHE—Metabolism—ABCB1—esophageal cancer	3.83e-06	7.26e-05	CbGpPWpGaD
Irinotecan—CYP2B6—Metabolism—CYP2A6—esophageal cancer	3.81e-06	7.24e-05	CbGpPWpGaD
Irinotecan—SLCO1B1—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	3.81e-06	7.23e-05	CbGpPWpGaD
Irinotecan—CYP3A5—Metabolism—GSTT1—esophageal cancer	3.77e-06	7.16e-05	CbGpPWpGaD
Irinotecan—SLCO1B1—Metabolism—ABCB1—esophageal cancer	3.73e-06	7.08e-05	CbGpPWpGaD
Irinotecan—CYP3A5—Metabolism—CYP2A6—esophageal cancer	3.73e-06	7.07e-05	CbGpPWpGaD
Irinotecan—ABCB1—Metabolism—GSTO1—esophageal cancer	3.67e-06	6.97e-05	CbGpPWpGaD
Irinotecan—ABCB1—Metabolism—TPI1—esophageal cancer	3.67e-06	6.97e-05	CbGpPWpGaD
Irinotecan—ALB—Metabolism—GNG7—esophageal cancer	3.64e-06	6.92e-05	CbGpPWpGaD
Irinotecan—SLC22A3—Metabolism—CREBBP—esophageal cancer	3.64e-06	6.91e-05	CbGpPWpGaD
Irinotecan—CYP2B6—Metabolism—PTGS1—esophageal cancer	3.62e-06	6.86e-05	CbGpPWpGaD
Irinotecan—CYP2B6—Metabolism—ENO1—esophageal cancer	3.62e-06	6.86e-05	CbGpPWpGaD
Irinotecan—ABCG2—Metabolism—HMOX1—esophageal cancer	3.6e-06	6.83e-05	CbGpPWpGaD
Irinotecan—CYP3A7—Metabolism—HMOX1—esophageal cancer	3.57e-06	6.77e-05	CbGpPWpGaD
Irinotecan—CYP2B6—Metabolism—PSME2—esophageal cancer	3.56e-06	6.76e-05	CbGpPWpGaD
Irinotecan—CYP2B6—Metabolism—PSME1—esophageal cancer	3.56e-06	6.76e-05	CbGpPWpGaD
Irinotecan—CYP3A5—Metabolism—ENO1—esophageal cancer	3.53e-06	6.71e-05	CbGpPWpGaD
Irinotecan—CYP3A5—Metabolism—PTGS1—esophageal cancer	3.53e-06	6.71e-05	CbGpPWpGaD
Irinotecan—ABCB1—Metabolism—ALDOB—esophageal cancer	3.52e-06	6.68e-05	CbGpPWpGaD
Irinotecan—ALB—Hemostasis—CREBBP—esophageal cancer	3.51e-06	6.67e-05	CbGpPWpGaD
Irinotecan—CYP3A4—Metabolism—SLC10A2—esophageal cancer	3.51e-06	6.66e-05	CbGpPWpGaD
Irinotecan—CYP3A4—Metabolism—CA1—esophageal cancer	3.51e-06	6.66e-05	CbGpPWpGaD
Irinotecan—ABCC1—Disease—NOS2—esophageal cancer	3.49e-06	6.62e-05	CbGpPWpGaD
Irinotecan—CYP3A5—Metabolism—PSME2—esophageal cancer	3.48e-06	6.61e-05	CbGpPWpGaD
Irinotecan—CYP3A5—Metabolism—PSME1—esophageal cancer	3.48e-06	6.61e-05	CbGpPWpGaD
Irinotecan—ABCC1—Disease—NOTCH1—esophageal cancer	3.46e-06	6.56e-05	CbGpPWpGaD
Irinotecan—ABCG2—Metabolism—ABCB1—esophageal cancer	3.45e-06	6.55e-05	CbGpPWpGaD
Irinotecan—ALB—Platelet activation, signaling and aggregation—PIK3CA—esophageal cancer	3.43e-06	6.52e-05	CbGpPWpGaD
Irinotecan—CYP3A7—Metabolism—ABCB1—esophageal cancer	3.42e-06	6.5e-05	CbGpPWpGaD
Irinotecan—ALB—Metabolism—ALDH2—esophageal cancer	3.42e-06	6.48e-05	CbGpPWpGaD
Irinotecan—ABCB1—Metabolism—GAPDH—esophageal cancer	3.39e-06	6.43e-05	CbGpPWpGaD
Irinotecan—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—esophageal cancer	3.38e-06	6.42e-05	CbGpPWpGaD
Irinotecan—ABCB1—Metabolism—CRABP1—esophageal cancer	3.36e-06	6.37e-05	CbGpPWpGaD
Irinotecan—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—esophageal cancer	3.27e-06	6.21e-05	CbGpPWpGaD
Irinotecan—SLC22A3—Metabolism—NOS3—esophageal cancer	3.26e-06	6.19e-05	CbGpPWpGaD
Irinotecan—ALB—Metabolism—GSTT1—esophageal cancer	3.25e-06	6.16e-05	CbGpPWpGaD
Irinotecan—ACHE—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	3.24e-06	6.16e-05	CbGpPWpGaD
Irinotecan—ALB—Metabolism—CYP2A6—esophageal cancer	3.21e-06	6.09e-05	CbGpPWpGaD
Irinotecan—CYP3A4—Metabolism—CA2—esophageal cancer	3.21e-06	6.09e-05	CbGpPWpGaD
Irinotecan—ALB—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	3.2e-06	6.07e-05	CbGpPWpGaD
Irinotecan—ABCB1—Metabolism—GNG7—esophageal cancer	3.19e-06	6.06e-05	CbGpPWpGaD
Irinotecan—ALB—Hemostasis—NOS3—esophageal cancer	3.15e-06	5.97e-05	CbGpPWpGaD
Irinotecan—ABCC1—Disease—CREBBP—esophageal cancer	3.13e-06	5.94e-05	CbGpPWpGaD
Irinotecan—UGT1A9—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	3.08e-06	5.84e-05	CbGpPWpGaD
Irinotecan—CYP2B6—Metabolism—CYP1B1—esophageal cancer	3.08e-06	5.83e-05	CbGpPWpGaD
Irinotecan—ALB—Metabolism—ENO1—esophageal cancer	3.04e-06	5.78e-05	CbGpPWpGaD
Irinotecan—ALB—Metabolism—PTGS1—esophageal cancer	3.04e-06	5.78e-05	CbGpPWpGaD
Irinotecan—ALB—Transmembrane transport of small molecules—CREBBP—esophageal cancer	3.04e-06	5.77e-05	CbGpPWpGaD
Irinotecan—CYP3A5—Metabolism—CYP1B1—esophageal cancer	3.01e-06	5.7e-05	CbGpPWpGaD
Irinotecan—ALB—Metabolism—PSME1—esophageal cancer	3e-06	5.69e-05	CbGpPWpGaD
Irinotecan—ALB—Metabolism—PSME2—esophageal cancer	3e-06	5.69e-05	CbGpPWpGaD
Irinotecan—ABCB1—Metabolism—ALDH2—esophageal cancer	2.99e-06	5.68e-05	CbGpPWpGaD
Irinotecan—CYP3A4—Metabolism—ADH7—esophageal cancer	2.98e-06	5.66e-05	CbGpPWpGaD
Irinotecan—CYP3A4—Metabolism—PLCE1—esophageal cancer	2.98e-06	5.66e-05	CbGpPWpGaD
Irinotecan—SLC22A3—Metabolism—PTGS2—esophageal cancer	2.98e-06	5.66e-05	CbGpPWpGaD
Irinotecan—ABCC1—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	2.97e-06	5.63e-05	CbGpPWpGaD
Irinotecan—BCHE—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	2.89e-06	5.49e-05	CbGpPWpGaD
Irinotecan—CYP2B6—Metabolism—CYP19A1—esophageal cancer	2.89e-06	5.49e-05	CbGpPWpGaD
Irinotecan—ACHE—Metabolism—CREBBP—esophageal cancer	2.87e-06	5.44e-05	CbGpPWpGaD
Irinotecan—ABCB1—Metabolism—GSTT1—esophageal cancer	2.85e-06	5.4e-05	CbGpPWpGaD
Irinotecan—CYP3A5—Metabolism—CYP19A1—esophageal cancer	2.83e-06	5.36e-05	CbGpPWpGaD
Irinotecan—SLCO1B1—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	2.82e-06	5.35e-05	CbGpPWpGaD
Irinotecan—ABCB1—Metabolism—CYP2A6—esophageal cancer	2.81e-06	5.34e-05	CbGpPWpGaD
Irinotecan—ABCC1—Disease—NOS3—esophageal cancer	2.81e-06	5.32e-05	CbGpPWpGaD
Irinotecan—UGT1A1—Metabolism—CREBBP—esophageal cancer	2.72e-06	5.16e-05	CbGpPWpGaD
Irinotecan—UGT1A9—Metabolism—CREBBP—esophageal cancer	2.72e-06	5.16e-05	CbGpPWpGaD
Irinotecan—ABCB1—Metabolism—ENO1—esophageal cancer	2.67e-06	5.06e-05	CbGpPWpGaD
Irinotecan—ABCB1—Metabolism—PTGS1—esophageal cancer	2.67e-06	5.06e-05	CbGpPWpGaD
Irinotecan—ABCB1—Transmembrane transport of small molecules—CREBBP—esophageal cancer	2.67e-06	5.06e-05	CbGpPWpGaD
Irinotecan—CYP2B6—Metabolism—HMOX1—esophageal cancer	2.64e-06	5.01e-05	CbGpPWpGaD
Irinotecan—ABCB1—Metabolism—PSME1—esophageal cancer	2.63e-06	4.99e-05	CbGpPWpGaD
Irinotecan—ABCB1—Metabolism—PSME2—esophageal cancer	2.63e-06	4.99e-05	CbGpPWpGaD
Irinotecan—ABCC1—Metabolism—CREBBP—esophageal cancer	2.62e-06	4.98e-05	CbGpPWpGaD
Irinotecan—ABCC1—Disease—ERBB2—esophageal cancer	2.62e-06	4.98e-05	CbGpPWpGaD
Irinotecan—ALB—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	2.62e-06	4.97e-05	CbGpPWpGaD
Irinotecan—CYP3A4—Metabolism—ADH1B—esophageal cancer	2.62e-06	4.97e-05	CbGpPWpGaD
Irinotecan—ALB—Metabolism—CYP1B1—esophageal cancer	2.59e-06	4.91e-05	CbGpPWpGaD
Irinotecan—CYP3A5—Metabolism—HMOX1—esophageal cancer	2.58e-06	4.89e-05	CbGpPWpGaD
Irinotecan—ACHE—Metabolism—NOS3—esophageal cancer	2.57e-06	4.87e-05	CbGpPWpGaD
Irinotecan—ABCC1—Disease—PTGS2—esophageal cancer	2.57e-06	4.87e-05	CbGpPWpGaD
Irinotecan—BCHE—Metabolism—CREBBP—esophageal cancer	2.56e-06	4.85e-05	CbGpPWpGaD
Irinotecan—CYP2B6—Metabolism—ABCB1—esophageal cancer	2.53e-06	4.8e-05	CbGpPWpGaD
Irinotecan—CYP3A4—Metabolism—TYMP—esophageal cancer	2.5e-06	4.75e-05	CbGpPWpGaD
Irinotecan—SLCO1B1—Metabolism—CREBBP—esophageal cancer	2.49e-06	4.73e-05	CbGpPWpGaD
Irinotecan—SLC22A3—Metabolism—EP300—esophageal cancer	2.48e-06	4.71e-05	CbGpPWpGaD
Irinotecan—CYP3A5—Metabolism—ABCB1—esophageal cancer	2.48e-06	4.7e-05	CbGpPWpGaD
Irinotecan—UGT1A1—Metabolism—NOS3—esophageal cancer	2.44e-06	4.62e-05	CbGpPWpGaD
Irinotecan—UGT1A9—Metabolism—NOS3—esophageal cancer	2.44e-06	4.62e-05	CbGpPWpGaD
Irinotecan—ALB—Metabolism—CYP19A1—esophageal cancer	2.43e-06	4.62e-05	CbGpPWpGaD
Irinotecan—CYP3A4—Metabolism—CYP26A1—esophageal cancer	2.43e-06	4.62e-05	CbGpPWpGaD
Irinotecan—ALB—Hemostasis—EP300—esophageal cancer	2.39e-06	4.54e-05	CbGpPWpGaD
Irinotecan—CYP3A4—Metabolism—ALOX15—esophageal cancer	2.37e-06	4.5e-05	CbGpPWpGaD
Irinotecan—ABCC1—Metabolism—NOS3—esophageal cancer	2.35e-06	4.46e-05	CbGpPWpGaD
Irinotecan—ACHE—Metabolism—PTGS2—esophageal cancer	2.35e-06	4.46e-05	CbGpPWpGaD
Irinotecan—ABCG2—Metabolism—CREBBP—esophageal cancer	2.31e-06	4.38e-05	CbGpPWpGaD
Irinotecan—BCHE—Metabolism—NOS3—esophageal cancer	2.29e-06	4.35e-05	CbGpPWpGaD
Irinotecan—CYP3A7—Metabolism—CREBBP—esophageal cancer	2.29e-06	4.34e-05	CbGpPWpGaD
Irinotecan—ABCB1—Metabolism—CYP1B1—esophageal cancer	2.27e-06	4.3e-05	CbGpPWpGaD
Irinotecan—CYP3A4—Metabolism—GSTO1—esophageal cancer	2.26e-06	4.29e-05	CbGpPWpGaD
Irinotecan—CYP3A4—Metabolism—TPI1—esophageal cancer	2.26e-06	4.29e-05	CbGpPWpGaD
Irinotecan—ABCC1—Disease—CDKN1A—esophageal cancer	2.24e-06	4.25e-05	CbGpPWpGaD
Irinotecan—SLCO1B1—Metabolism—NOS3—esophageal cancer	2.23e-06	4.24e-05	CbGpPWpGaD
Irinotecan—UGT1A1—Metabolism—PTGS2—esophageal cancer	2.23e-06	4.23e-05	CbGpPWpGaD
Irinotecan—UGT1A9—Metabolism—PTGS2—esophageal cancer	2.23e-06	4.23e-05	CbGpPWpGaD
Irinotecan—ALB—Metabolism—HMOX1—esophageal cancer	2.22e-06	4.21e-05	CbGpPWpGaD
Irinotecan—ALB—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	2.18e-06	4.13e-05	CbGpPWpGaD
Irinotecan—CYP3A4—Metabolism—ALDOB—esophageal cancer	2.17e-06	4.11e-05	CbGpPWpGaD
Irinotecan—ABCC1—Metabolism—PTGS2—esophageal cancer	2.15e-06	4.08e-05	CbGpPWpGaD
Irinotecan—ABCC1—Disease—EP300—esophageal cancer	2.13e-06	4.05e-05	CbGpPWpGaD
Irinotecan—ABCB1—Metabolism—CYP19A1—esophageal cancer	2.13e-06	4.05e-05	CbGpPWpGaD
Irinotecan—ALB—Metabolism—ABCB1—esophageal cancer	2.13e-06	4.04e-05	CbGpPWpGaD
Irinotecan—BCHE—Metabolism—PTGS2—esophageal cancer	2.09e-06	3.97e-05	CbGpPWpGaD
Irinotecan—CYP3A4—Metabolism—GAPDH—esophageal cancer	2.09e-06	3.96e-05	CbGpPWpGaD
Irinotecan—CYP3A4—Metabolism—CRABP1—esophageal cancer	2.07e-06	3.92e-05	CbGpPWpGaD
Irinotecan—ABCG2—Metabolism—NOS3—esophageal cancer	2.07e-06	3.92e-05	CbGpPWpGaD
Irinotecan—CYP3A7—Metabolism—NOS3—esophageal cancer	2.05e-06	3.89e-05	CbGpPWpGaD
Irinotecan—SLCO1B1—Metabolism—PTGS2—esophageal cancer	2.04e-06	3.87e-05	CbGpPWpGaD
Irinotecan—CYP3A4—Metabolism—GNG7—esophageal cancer	1.97e-06	3.73e-05	CbGpPWpGaD
Irinotecan—ACHE—Metabolism—EP300—esophageal cancer	1.95e-06	3.71e-05	CbGpPWpGaD
Irinotecan—ABCB1—Metabolism—HMOX1—esophageal cancer	1.95e-06	3.69e-05	CbGpPWpGaD
Irinotecan—ABCG2—Metabolism—PTGS2—esophageal cancer	1.89e-06	3.59e-05	CbGpPWpGaD
Irinotecan—CYP3A7—Metabolism—PTGS2—esophageal cancer	1.87e-06	3.56e-05	CbGpPWpGaD
Irinotecan—ABCC1—Disease—MYC—esophageal cancer	1.86e-06	3.53e-05	CbGpPWpGaD
Irinotecan—UGT1A1—Metabolism—EP300—esophageal cancer	1.85e-06	3.52e-05	CbGpPWpGaD
Irinotecan—UGT1A9—Metabolism—EP300—esophageal cancer	1.85e-06	3.52e-05	CbGpPWpGaD
Irinotecan—CYP3A4—Metabolism—ALDH2—esophageal cancer	1.84e-06	3.5e-05	CbGpPWpGaD
Irinotecan—SLC22A3—Metabolism—PIK3CA—esophageal cancer	1.84e-06	3.48e-05	CbGpPWpGaD
Irinotecan—ABCC1—Disease—EGFR—esophageal cancer	1.82e-06	3.45e-05	CbGpPWpGaD
Irinotecan—ABCC1—Metabolism—EP300—esophageal cancer	1.79e-06	3.39e-05	CbGpPWpGaD
Irinotecan—ALB—Hemostasis—PIK3CA—esophageal cancer	1.77e-06	3.36e-05	CbGpPWpGaD
Irinotecan—CYP3A4—Metabolism—GSTT1—esophageal cancer	1.75e-06	3.33e-05	CbGpPWpGaD
Irinotecan—BCHE—Metabolism—EP300—esophageal cancer	1.74e-06	3.31e-05	CbGpPWpGaD
Irinotecan—CYP3A4—Metabolism—CYP2A6—esophageal cancer	1.73e-06	3.29e-05	CbGpPWpGaD
Irinotecan—ALB—Hemostasis—TP53—esophageal cancer	1.71e-06	3.25e-05	CbGpPWpGaD
Irinotecan—SLCO1B1—Metabolism—EP300—esophageal cancer	1.7e-06	3.22e-05	CbGpPWpGaD
Irinotecan—CYP2B6—Metabolism—CREBBP—esophageal cancer	1.69e-06	3.21e-05	CbGpPWpGaD
Irinotecan—CYP3A5—Metabolism—CREBBP—esophageal cancer	1.65e-06	3.14e-05	CbGpPWpGaD
Irinotecan—CYP3A4—Metabolism—ENO1—esophageal cancer	1.64e-06	3.12e-05	CbGpPWpGaD
Irinotecan—CYP3A4—Metabolism—PTGS1—esophageal cancer	1.64e-06	3.12e-05	CbGpPWpGaD
Irinotecan—CYP3A4—Metabolism—PSME2—esophageal cancer	1.62e-06	3.07e-05	CbGpPWpGaD
Irinotecan—CYP3A4—Metabolism—PSME1—esophageal cancer	1.62e-06	3.07e-05	CbGpPWpGaD
Irinotecan—ALB—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	1.61e-06	3.06e-05	CbGpPWpGaD
Irinotecan—ABCC1—Disease—PIK3CA—esophageal cancer	1.58e-06	2.99e-05	CbGpPWpGaD
Irinotecan—ABCG2—Metabolism—EP300—esophageal cancer	1.57e-06	2.98e-05	CbGpPWpGaD
Irinotecan—CYP3A7—Metabolism—EP300—esophageal cancer	1.56e-06	2.96e-05	CbGpPWpGaD
Irinotecan—CYP2B6—Metabolism—NOS3—esophageal cancer	1.52e-06	2.87e-05	CbGpPWpGaD
Irinotecan—CYP3A5—Metabolism—NOS3—esophageal cancer	1.48e-06	2.81e-05	CbGpPWpGaD
Irinotecan—ACHE—Metabolism—PIK3CA—esophageal cancer	1.44e-06	2.74e-05	CbGpPWpGaD
Irinotecan—ALB—Metabolism—CREBBP—esophageal cancer	1.42e-06	2.7e-05	CbGpPWpGaD
Irinotecan—CYP3A4—Metabolism—CYP1B1—esophageal cancer	1.4e-06	2.65e-05	CbGpPWpGaD
Irinotecan—CYP2B6—Metabolism—PTGS2—esophageal cancer	1.39e-06	2.63e-05	CbGpPWpGaD
Irinotecan—UGT1A1—Metabolism—PIK3CA—esophageal cancer	1.37e-06	2.6e-05	CbGpPWpGaD
Irinotecan—UGT1A9—Metabolism—PIK3CA—esophageal cancer	1.37e-06	2.6e-05	CbGpPWpGaD
Irinotecan—CYP3A5—Metabolism—PTGS2—esophageal cancer	1.35e-06	2.57e-05	CbGpPWpGaD
Irinotecan—ABCC1—Metabolism—PIK3CA—esophageal cancer	1.32e-06	2.51e-05	CbGpPWpGaD
Irinotecan—CYP3A4—Metabolism—CYP19A1—esophageal cancer	1.31e-06	2.49e-05	CbGpPWpGaD
Irinotecan—BCHE—Metabolism—PIK3CA—esophageal cancer	1.29e-06	2.45e-05	CbGpPWpGaD
Irinotecan—ALB—Metabolism—NOS3—esophageal cancer	1.28e-06	2.42e-05	CbGpPWpGaD
Irinotecan—SLCO1B1—Metabolism—PIK3CA—esophageal cancer	1.26e-06	2.38e-05	CbGpPWpGaD
Irinotecan—ABCB1—Metabolism—CREBBP—esophageal cancer	1.25e-06	2.37e-05	CbGpPWpGaD
Irinotecan—CYP3A4—Metabolism—HMOX1—esophageal cancer	1.2e-06	2.27e-05	CbGpPWpGaD
Irinotecan—ALB—Metabolism—PTGS2—esophageal cancer	1.17e-06	2.21e-05	CbGpPWpGaD
Irinotecan—ABCG2—Metabolism—PIK3CA—esophageal cancer	1.16e-06	2.21e-05	CbGpPWpGaD
Irinotecan—CYP3A7—Metabolism—PIK3CA—esophageal cancer	1.15e-06	2.19e-05	CbGpPWpGaD
Irinotecan—CYP2B6—Metabolism—EP300—esophageal cancer	1.15e-06	2.19e-05	CbGpPWpGaD
Irinotecan—CYP3A4—Metabolism—ABCB1—esophageal cancer	1.15e-06	2.18e-05	CbGpPWpGaD
Irinotecan—CYP3A5—Metabolism—EP300—esophageal cancer	1.13e-06	2.14e-05	CbGpPWpGaD
Irinotecan—ABCB1—Metabolism—NOS3—esophageal cancer	1.12e-06	2.12e-05	CbGpPWpGaD
Irinotecan—ABCB1—Metabolism—PTGS2—esophageal cancer	1.02e-06	1.94e-05	CbGpPWpGaD
Irinotecan—ALB—Metabolism—EP300—esophageal cancer	9.7e-07	1.84e-05	CbGpPWpGaD
Irinotecan—CYP2B6—Metabolism—PIK3CA—esophageal cancer	8.53e-07	1.62e-05	CbGpPWpGaD
Irinotecan—ABCB1—Metabolism—EP300—esophageal cancer	8.5e-07	1.61e-05	CbGpPWpGaD
Irinotecan—CYP3A5—Metabolism—PIK3CA—esophageal cancer	8.33e-07	1.58e-05	CbGpPWpGaD
Irinotecan—CYP3A4—Metabolism—CREBBP—esophageal cancer	7.69e-07	1.46e-05	CbGpPWpGaD
Irinotecan—ALB—Metabolism—PIK3CA—esophageal cancer	7.18e-07	1.36e-05	CbGpPWpGaD
Irinotecan—CYP3A4—Metabolism—NOS3—esophageal cancer	6.89e-07	1.31e-05	CbGpPWpGaD
Irinotecan—CYP3A4—Metabolism—PTGS2—esophageal cancer	6.3e-07	1.19e-05	CbGpPWpGaD
Irinotecan—ABCB1—Metabolism—PIK3CA—esophageal cancer	6.29e-07	1.19e-05	CbGpPWpGaD
Irinotecan—CYP3A4—Metabolism—EP300—esophageal cancer	5.24e-07	9.94e-06	CbGpPWpGaD
Irinotecan—CYP3A4—Metabolism—PIK3CA—esophageal cancer	3.87e-07	7.35e-06	CbGpPWpGaD
